Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Recent & Breaking News (NDAQ:EXEL)

Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress

Business Wire August 1, 2017

Technical Snapshots for These Biotech Stocks -- Exelixis, Celldex Therapeutics, Clovis Oncology, and Geron

PR Newswire July 24, 2017

Exelixis Announces Settlement of Dispute with Genentech Regarding Companies’ Collaboration Agreement for Cobimetinib

Business Wire July 20, 2017

Exelixis to Release Second Quarter 2017 Financial Results on Wednesday, August 2, 2017

Business Wire July 17, 2017

Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Business Wire July 10, 2017

Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness

Business Wire June 29, 2017

Mid-Morning Market Update: Markets Mostly Higher; CarMax Tops Q1 Expectations

Benzinga.com  June 21, 2017

15 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  June 19, 2017

Exelixis Announces Independent Radiology Committee Review Confirms Results from CABOSUN, the Phase 2 Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma

Business Wire June 19, 2017

Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

Business Wire June 12, 2017

Exelixis to Present at the William Blair & Co. 37th Annual Growth Stock Conference on June 13

Business Wire June 8, 2017

Stifel's ASCO Abstract Cheat Sheet

Benzinga.com  May 18, 2017

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire May 3, 2017

18 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  May 2, 2017

Investors: Covered Call reports for Exelixis, Facebook, Priceline, Pfizer Inc. and AT&T include trade ideas that offer returns of 18% or more!

PR Newswire May 2, 2017

Exelixis Announces First Quarter 2017 Financial Results and Provides Corporate Update

Business Wire May 1, 2017

Investor Network: Exelixis, Inc. to Host Earnings Call

Accesswire May 1, 2017

Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3

Business Wire April 24, 2017

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Business Wire April 4, 2017

Exelixis Further Reduces Indebtedness by Repaying Silicon Valley Bank Term Loan

Business Wire March 29, 2017